Meadow Foxtail Grass Allergy: Early-Season Pollen and Pooideae Cross-Reactivity

Meadow foxtail (Alopecurus pratensis) typically begins releasing pollen in late April to early May in the southern part of its northern US range, and peaks through June in cooler northern regions and at higher elevations. This makes it an early-season grass — blooming two to four weeks before the main grass season peak established by timothy and Kentucky bluegrass in June and July. In New England, the Pacific Northwest, and Rocky Mountain meadows, meadow foxtail is often the first significant grass pollen detected at NAB monitoring stations each spring. Patients sensitized to meadow foxtail should begin pharmacotherapy in mid-April to be fully medicated before first pollen counts appear.

Meadow foxtail (Alopecurus pratensis) and foxtail millet (Setaria italica) share 'foxtail' in their common names but are completely different plants in different Poaceae subfamilies. Meadow foxtail is a Pooideae pasture grass — in the same subfamily as timothy, Kentucky bluegrass, and orchard grass, with highly cross-reactive group-1 and group-5 allergens. It is a perennial aeroallergen with a May–June blooming season in temperate northern US locations. Foxtail millet is a Panicoideae cereal grain — in the same subfamily as Bermuda grass, Johnson grass, and corn — with a different allergen profile that cross-reacts poorly with Pooideae. Foxtail millet also has a dietary exposure route (grain food) and occupational exposure route (birdseed) that meadow foxtail does not. Timothy SLIT treats meadow foxtail; it does NOT fully cover Panicoideae sensitization from foxtail millet.

Meadow foxtail (Alopecurus pratensis) is a European grass introduced to North America and now widely naturalized across the northern United States. It grows abundantly in northern New England, the Pacific Northwest, the Great Lakes region, the northern Plains states, and Rocky Mountain meadows and pastures. It favors moist meadows, pasture land, roadsides, streambanks, and disturbed ground at low to mid elevations. It does not grow in significant quantities in the southern or southwestern US, which is why its clinical significance is greatest for patients in the northern tier states. If you are in the Southeast or Southwest and have grass allergy, your primary Pooideae allergens are more likely to be Bermuda grass (Panicoideae) or local subspecies of Timothy and Kentucky bluegrass.

Yes — Alopecurus pratensis (meadow foxtail) is explicitly named as one of the five grass species in the Oralair 5-grass sublingual immunotherapy tablet, approved by the FDA in 2014 for patients aged 5 to 65. The five grasses in Oralair are: timothy (Phleum pratense), orchard grass (Dactylis glomerata), perennial ryegrass (Lolium perenne), Kentucky bluegrass (Poa pratensis), and meadow foxtail (Alopecurus pratensis). This explicit inclusion makes meadow foxtail one of the best-characterized niche grass aeroallergens in the US immunotherapy formulary. Grastek (the timothy-only SLIT tablet) covers meadow foxtail through Pooideae cross-reactivity but does not name it explicitly in the composition.

Yes, through Pooideae cross-reactivity. Timothy (Phleum pratense) contains Phl p 1 and Phl p 5 — group-1 and group-5 grass allergens that share over 80% sequence identity with Alopecurus pratensis's Alo p 1 and Alo p 5. IgE antibodies raised against Phl p 1 cross-link Alo p 1 and vice versa, meaning immune tolerance built toward timothy allergens extends to meadow foxtail through the same mechanism. The Grastek timothy SLIT tablet (FDA-approved 2014) provides clinical benefit for the whole Pooideae subfamily on this basis. However, Oralair explicitly contains meadow foxtail and is considered the more inclusive product for patients who want explicit multi-grass coverage.

Alo p 1 is the primary allergen of Alopecurus pratensis (meadow foxtail) — a beta-expansin protein classified as a group-1 grass allergen, approximately 30 kilodaltons in size. It is formally named in the WHO/IUIS allergen nomenclature database. If your allergy test shows IgE reactivity to Alo p 1 (or meadow foxtail g16 on the Thermo Fisher Phadia panel), it confirms IgE-mediated sensitization to the Pooideae grass family through the group-1 allergen pathway. Because group-1 allergens are highly cross-reactive across Pooideae species, an Alo p 1 positive result also implies sensitization to timothy Phl p 1, Kentucky bluegrass Poa p 1, orchard grass Dac g 1, and ryegrass Lol p 1 — the full Pooideae cluster that Oralair and Grastek target.

If your grass allergy symptoms begin in May — before the June peak associated with timothy and Kentucky bluegrass — you are likely sensitized to early-season Pooideae grasses including meadow foxtail (Alopecurus pratensis), sweet vernal grass (Anthoxanthum odoratum), and orchard grass (Dactylis glomerata). These species bloom two to four weeks earlier than the main grass season in temperate northern US locations. Meadow foxtail is often detected at NAB monitoring stations from late April onward, with peak counts in May and early June. If you start your allergy medications in June thinking that's when grass season begins, you are already well into your symptom window — begin treatment in mid-April for optimal pre-seasonal protection.

Yes — both FDA-approved grass SLIT tablets (Oralair and Grastek) are approved for patients aged 5 and older. Subcutaneous immunotherapy (SCIT/allergy shots) is typically considered for children aged 5 and older as well, though the lower age limit varies by practice. Children benefit substantially from grass immunotherapy — clinical data suggest early immunotherapy initiation may reduce the risk of developing new allergic sensitizations and may reduce asthma development in atopic children with grass rhinitis. Both SLIT tablets require allergen-free observation for the first dose, and Oralair requires the first dose to be administered in an allergist's office. After the first dose, both tablets are taken at home.

No. Grass pollen allergens — including Pooideae group-1 proteins like Alo p 1 — do not produce the food cross-reactions (oral allergy syndrome, OAS) associated with birch PR-10 proteins. OAS to raw apple, cherry, peach, hazelnut, soy, celery, and carrot is driven by IgE cross-reactivity with birch Bet v 1, not with grass allergens. If you have grass pollen allergy AND OAS to raw fruits, these are two separate sensitization events — the OAS is from birch, not grass. The exception: some patients with high IgE loads to profilin (a panallergen) may show cross-reactivity to both grass pollen and some plant foods through the profilin pathway, but this is a different and typically milder mechanism than the birch PR-10 OAS that most patients experience.

Meadow foxtail (Alopecurus pratensis) is a non-native European grass that has naturalized across the northern United States, but its invasive status varies by region and context. In some northern US agricultural areas, it can spread aggressively in moist pastures and compete with native vegetation. However, it is not listed as an aggressive invasive species at the federal level and is managed differently from true invasive grasses like Japanese stiltgrass or buffelgrass. In many regions, it is simply considered a naturalized agricultural grass. Its ecological status is less important for allergy management than its phenology — the fact that it blooms earlier than the main grass season and is an explicit Oralair component makes it clinically significant regardless of its invasive classification.